Pathology confronts molecular targeted therapies
Jose Costa
This article has no abstract so we have provided the first paragraph of the full text.
Until very recently, pathological diagnosis combined with diagnostic imaging was used to guide therapy and predict prognosis for practically all patients with cancer. Histopathological classification and grading have been the major elements in determining patient management, and have largely been used to guide epidemiological, therapeutic and mechanistic studies by providing sufficiently robust criteria to classify neoplastic diseases. Now we can design specific methods to target dysfunction at the molecular level to induce cancer cell death, or to sensitize cancer cells to conventional therapeutic modalities. Molecular diagnosis of tumors enables the characterization of many of the pathogenetic abnormalities in 'cancer genes' that are present in tissue biopsies.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.